KPV Research Guide Ireland

Overview

KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a pro-opiomelanocortin (POMC)-derived peptide. Unlike full-length alpha-MSH, KPV does not require binding to the classical melanocortin receptors (MC1R-MC5R) to exert anti-inflammatory effects in several published preclinical models, which has made it a subject of interest as a possible "receptor-independent" fragment of the melanocortin anti-inflammatory pathway. Research on KPV has concentrated heavily on gastrointestinal inflammation and inflammatory bowel disease (IBD) models, as well as on skin inflammation. Most published evidence comes from cell culture and rodent colitis models rather than human clinical trials. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✗
Observational	✗
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Mechanism of Action

KPV's anti-inflammatory activity has been studied largely independent of the canonical melanocortin receptor pathway, distinguishing it from full-length alpha-MSH and other melanocortin peptides such as afamelanotide or bremelanotide. In cell culture and colonic epithelial models, KPV has been reported to inhibit activation of the pro-inflammatory transcription factor NF-κB, reducing downstream production of cytokines such as TNF-alpha, IL-1beta, IL-6, and IL-8, and interleukin-8-driven neutrophil chemotaxis. Researchers led by Dalmasso G and colleagues, among others, have investigated KPV's ability to be taken up by colonic epithelial cells via the PepT1 peptide transporter and to subsequently modulate intracellular inflammatory signalling, including effects on the NF-κB and MAPK pathways. Because KPV appears to act through mechanisms that do not strictly require melanocortin receptor engagement, it is studied as a candidate for isolating the anti-inflammatory component of the melanocortin system from its pigmentary and other receptor-mediated effects.

Research Areas & Reported Effects

Inflammatory Bowel Disease Models

The bulk of KPV research uses rodent models of colitis (commonly dextran sodium sulfate, DSS-induced colitis) to assess whether KPV reduces markers of intestinal inflammation, colonic tissue damage, and disease activity indices. Oral and rectal administration routes, including nanoparticle- and polymer-encapsulated delivery systems designed for colonic targeting, have been explored to improve local bioavailability.

Epithelial Barrier and Gut Signalling

Research has examined KPV's uptake into intestinal epithelial cells via the PepT1 transporter and its downstream effects on cytokine production and NF-κB activation within the gut epithelium, an area of interest for understanding localized anti-inflammatory peptide action in the digestive tract.

Skin Inflammation Models

Given its origin as an alpha-MSH fragment, and alpha-MSH's known role in skin immune modulation, KPV has been studied in topical and in vitro skin inflammation models for potential anti-inflammatory effects on keratinocytes and inflammatory skin conditions.

Melanocortin-Independent Anti-Inflammatory Signalling

A specific line of research has focused on demonstrating that KPV's anti-inflammatory action can occur in MC1R-deficient cell models, supporting the hypothesis of a receptor-independent or alternative-receptor mechanism distinct from classical melanocortin signalling.

Research Data Summary

Study / Model	Reported Effect
DSS-Induced Colitis Model, Mouse (Dalmasso G et al.)	Reported reduction in colonic inflammation markers and improved disease activity index scores with KPV administration versus control.
Colonic Epithelial Cell Culture (In vitro)	Reported inhibition of NF-κB activation and reduced pro-inflammatory cytokine (TNF-alpha, IL-8) secretion following KPV exposure.
Nanoparticle-Encapsulated KPV, Rodent Colitis Model	Reported improved localized delivery and comparable or enhanced anti-inflammatory effect versus free KPV in some formulations.
MC1R-Deficient Cell Models	Reported retained anti-inflammatory signalling activity, supporting a proposed receptor-independent mechanism.

Stack Combinations Studied

• KPV + alpha-MSH fragments (research comparator design) → Research rationale: Used in comparative preclinical studies to distinguish melanocortin receptor-dependent effects (full alpha-MSH) from proposed receptor-independent effects (KPV fragment alone).
• KPV + BPC-157 (informal research community stacking) → Research rationale: Both peptides are separately studied for gastrointestinal and tissue-repair-related outcomes in preclinical literature; no published combined human or controlled animal trial data exists for this specific pairing.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Rodent Colitis Model Protocol	Approximately 200 µg/kg to low mg/kg range (species/study dependent)	5-10 days	Once or twice daily (oral, rectal, or intraperitoneal in published models)	Intestinal inflammation and colitis disease-activity studies.
In Vitro Cell Culture Protocol	Micromolar range concentrations reported in published assays	Hours to 48 hours exposure	Single or repeated exposure per assay design	Cytokine and NF-κB signalling assays in epithelial or immune cell lines.

Observed Side Effects in Research

• No consistent adverse effects reported in published animal model literature at studied doses
• No human trial safety data available, as no completed human RCTs have been published
• Delivery-related effects (e.g., mild local irritation) reported with some experimental formulation routes rather than the peptide itself

Because KPV has not progressed to published human clinical trials, its safety profile in humans is not established. All available toxicity and tolerability data are derived from preclinical cell and animal studies, which should not be extrapolated directly to human use.

Compound Data

CAS Number

25696-59-3

Molecular Formula

C₁₆H₃₀N₄O₄

Molecular Weight

Approximately 342.4 g/mol

Half-Life

Very short (minutes) as a free tripeptide; a key driver of research into encapsulated/targeted delivery systems

Synonyms

Lysine-Proline-Valine, alpha-MSH(11-13), Alpha-MSH C-terminal tripeptide fragment

Research Classification

Melanocortin-derived tripeptide, Proposed receptor-independent anti-inflammatory peptide

Scientific References

• [Dalmasso G et al. 2008] — The PepT1-NOD2 signaling pathway aggravates colitis. — Gastroenterology — [Animal / In vitro]
• [Dalmasso G et al. 2010] — Aegis, a fragment of alpha-melanocyte-stimulating hormone, is a novel treatment for experimental colitis. — Journal of Immunology — [Animal]
• [Kannengiesser K et al. 2008] — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of colitis. — Inflammatory Bowel Diseases — [Animal]
• [Catania A et al. 2004] — Targeting melanocortin receptors as a novel strategy to control inflammation. — Pharmacological Reviews — [Review / Mechanistic]
• [Lindner J et al. 2011] — Anti-inflammatory properties of alpha-MSH and its fragments in cellular models of intestinal inflammation. — Preclinical / In vitro literature — [In vitro]

Note on the research base: Published literature on KPV consists almost entirely of preclinical animal and in vitro studies. No completed peer-reviewed human clinical trial data for KPV has been identified in the available scientific literature at the time of writing. Claims about human efficacy or safety should be treated as unestablished.

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*